IGC Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $24.28M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2012 Ended Jun 30, 2011 | Jul 15, 2011 | During market hours | – | – | – |
Press releases
Announcements IGC Pharma filed with the SEC
Advancing Alzheimer’s Care. Improving Lives. NYSE American: IGC
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
Other events · EX-99.1 to Form 8-K
IGC Pharma Announces Results of 2025 Annual
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Date: June 16, 2025 NYSEAmerican: IGC 1 NYSE AMERICAN: IGC - Service to humanity -
Other events · EX-99.1 to Form 8-K
IGC Announces Results of its 2024 Annual Stockholders Meeting
Shareholder vote results · Other events · EX-99.1 to Form 8-K
IGC Pharma Announces Positive Interim Results for IGC-AD1 in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED ON MARCH 26, 2024
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer ’ s Pipeline
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
IGC Announces Results of its 2023 Annual Stockholders Meeting
Shareholder vote results · Other events · EX-99.1 to Form 8-K
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
IGC Announces Updated Life Sciences Presentation
Regulation FD disclosure · EX-99.2 to Form 8-K